Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Parkinson disease | D010300 | EFO_0002508 | G20 | — | 3 | 2 | — | — | 3 |
Dyskinesias | D020820 | HP_0002310 | G24 | — | 3 | 2 | — | — | 3 |
Drug-induced dyskinesia | D004409 | EFO_1000904 | — | — | 2 | 2 | — | — | 2 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Dystonic disorders | D020821 | — | G24 | — | 1 | — | — | — | 1 |
Dystonia | D004421 | HP_0001332 | G24 | — | 1 | — | — | — | 1 |
Blepharospasm | D001764 | — | G24.5 | — | 1 | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Healthy volunteers/patients | — | — | — | 1 | — | — | — | — | 1 |
Drug common name | Dipraglurant |
INN | dipraglurant |
Description | Dipraglurant (INN) (code name ADX-48621) is a negative allosteric modulator of the mGlu5 receptor which is under development by Addex Therapeutics for the treatment of Parkinson's disease levodopa-induced dyskinesia (PD-LID). As of 2014, it is in phase II clinical trials for this indication. Addex Therapeutics is also investigating an extended-release formulation of dipraglurant for the treatment of non-parkinsonian dystonia.
|
Classification | Small molecule |
Drug class | metabotropic glutamate receptor antagonists, negative allosteric modulators |
Image (chem structure or protein) | |
Structure (InChI/SMILES or Protein Sequence) | Fc1ccc2nc(CCC#Cc3ccccn3)cn2c1 |
PDB | — |
CAS-ID | — |
RxCUI | — |
ChEMBL ID | CHEMBL2346738 |
ChEBI ID | — |
PubChem CID | 44557636 |
DrugBank | — |
UNII ID | CV8JZR21A1 (ChemIDplus, GSRS) |